Back to Research Library
Compound Profiles 12 min read

BPC-157: Research Overview

Detailed review of BPC-157 molecular mechanisms, research applications, and current literature.

Overview

BPC-157 (Body Protective Compound-157) is a laboratory-synthesised pentadecapeptide composed of 15 amino acids, derived from a partial sequence found within human gastric secretions. The full amino acid sequence reads: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.

Originally characterised in the early 1990s by a research group at the University of Zagreb, BPC-157 has since generated a considerable volume of preclinical literature examining its cytoprotective and tissue-regenerative properties.

Molecular Mechanisms

Vascular Growth Stimulation

Multiple rodent investigations have documented BPC-157's capacity to promote new blood vessel formation through enhanced VEGF (vascular endothelial growth factor) signalling activity. This pro-angiogenic effect is widely thought to underpin the peptide's observed wound healing activity across animal models.

Nitric Oxide System Interaction

Evidence suggests that BPC-157 engages with nitric oxide (NO) signalling pathways, influencing both eNOS (endothelial nitric oxide synthase) and nNOS (neuronal nitric oxide synthase) expression. NO plays an essential role in vascular tone regulation, neural signalling, and immune activity.

Growth Factor Expression Enhancement

Research has documented BPC-157's capacity to upregulate:

  • •EGR-1 (Early Growth Response Protein 1) — a transcription factor central to tissue repair signalling
  • •VEGFR2 — the key receptor mediating angiogenic responses to VEGF
  • •FAK (Focal Adhesion Kinase) — involved in cellular migration and wound closure processes

Tendon and Connective Tissue Research

BPC-157 has been widely studied in models of tendon healing. Research conducted at the University of Zagreb demonstrated faster tendon-to-bone repair in animal subjects, with histological examination revealing enhanced collagen organisation and elevated fibroblast activity in treated groups compared to controls.

Research Areas

Gastrointestinal Protection

The peptide's derivation from gastric secretions informed much of the early research focus. Studies in rodent systems have demonstrated protective properties against:

  • •NSAID-induced mucosal lesions
  • •Ethanol-associated gastric damage
  • •Experimentally induced colitis models

Musculoskeletal Repair

Currently among the most active areas of investigation:

  • •Tendon healing: Accelerated regeneration in Achilles tendon transection models
  • •Muscle repair: Enhanced recovery in crush-injury protocols
  • •Ligament repair: Improved outcomes in medial collateral ligament section studies

Neurological Investigations

A growing body of preclinical work examines BPC-157's role in neural systems:

  • •Interactions with dopaminergic signalling pathways
  • •Effects on serotonin-related activity
  • •Recovery outcomes in sciatic nerve crush injury models

Systemic Organ Research

BPC-157 appears to exhibit activity across multiple organ systems, with published research exploring:

  • •Hepatoprotective effects in alcohol-induced liver damage
  • •Cardioprotective properties in heart failure models
  • •Renal protective activity in cisplatin toxicity models

Stability and Research Administration

BPC-157 demonstrates notable stability in human gastric juice — a property consistent with its biological origin. For laboratory applications:

  • •Typically provided as lyophilised powder
  • •Reconstituted in bacteriostatic water or sterile saline
  • •Maintains stability at -20°C for extended periods following reconstitution

Current Research Landscape

The bulk of published BPC-157 research has originated from the University of Zagreb under Sikiric and colleagues, with over 100 peer-reviewed papers now on record. The preclinical evidence base is substantial, though translation to clinical research remains an active area of investigation.

Key publication venues include:

  • •Journal of Physiology – Paris
  • •Biomedicines
  • •Current Pharmaceutical Design
  • •Pharmacological Research

Purity Requirements

To ensure research reproducibility, BPC-157 should conform to:

  • •≥98% purity as verified by HPLC analysis
  • •Correct molecular weight confirmed via mass spectrometry: 1419.5 Da
  • •Provision of an independent third-party Certificate of Analysis

This article is intended for research and educational purposes only. BPC-157 is not approved for human therapeutic use.

Research Use Only: All products are sold strictly for in-vitro laboratory research purposes. Not for human or veterinary consumption. Not approved by the MHRA for any therapeutic use. Not intended to diagnose, treat, cure, or prevent any disease. Purchaser must be 18+ and a qualified researcher.

King Pharma

King Pharma is a UK-based supplier of independently verified, laboratory-grade peptide research compounds. All products are supplied for qualified scientific research use only.

⚠️ None of our products are intended for human use. No medicinal claims are made or implied.

© 2026 King Pharma Ltd. All rights reserved. Registered in England & Wales.

Secure payments:
VISAMCAMEXMaestro